View Item 

Show simple item record

Phase 1 doseâ finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer
dc.contributor.authorGulati, Shuchi
dc.contributor.authorDesai, Janki
dc.contributor.authorPalackdharry, Sarah M.
dc.contributor.authorMorris, John C.
dc.contributor.authorZhu, Zheng
dc.contributor.authorJandarov, Roman
dc.contributor.authorRiaz, Muhammad K.
dc.contributor.authorTakiar, Vinita
dc.contributor.authorMierzwa, Michelle
dc.contributor.authorGutkind, J. Silvio
dc.contributor.authorMolinolo, Alfredo
dc.contributor.authorDesai, Pankaj B.
dc.contributor.authorSadraei, Nooshin Hashemi
dc.contributor.authorWise‐draper, Trisha M.
dc.date.accessioned2020-01-13T15:19:59Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-01-13T15:19:59Z
dc.date.issued2020-01-15
dc.identifier.citationGulati, Shuchi; Desai, Janki; Palackdharry, Sarah M.; Morris, John C.; Zhu, Zheng; Jandarov, Roman; Riaz, Muhammad K.; Takiar, Vinita; Mierzwa, Michelle; Gutkind, J. Silvio; Molinolo, Alfredo; Desai, Pankaj B.; Sadraei, Nooshin Hashemi; Wise‐draper, Trisha M. (2020). "Phase 1 doseâ finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer." Cancer (2): 354-362.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/153201
dc.publisherWiley Periodicals, Inc.
dc.subject.othermetformin
dc.subject.otherclinical trial
dc.subject.otherhead and neck cancer
dc.subject.otherphase 1
dc.titlePhase 1 doseâ finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153201/1/cncr32539.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153201/2/cncr32539_am.pdf
dc.identifier.doi10.1002/cncr.32539
dc.identifier.sourceCancer
dc.identifier.citedreferenceXiang AH, Trigo E, Martinez M, et al; RISE Collaborators. Impact of gastric banding versus metformin on βâ cell function in adults with impaired glucose tolerance or mild type 2 diabetes. Diabetes Care. 2018; 41: 2544 â 2551.
dc.identifier.citedreferenceSurveillance, Epidemiology, and End Results. Common cancer sitesâ Cancer Stat Facts. Accessed June 10, 2019. https://seer.cancer.gov/statfacts/html/common.html
dc.identifier.citedreferenceBurgy M, Leblanc J, Borel C. Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma? Anticancer Drugs. 2018; 29: 287 â 294.
dc.identifier.citedreferenceHaddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018; 29: 1130 â 1140. doi: 10.1093/annonc/mdy102
dc.identifier.citedreferenceAng KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014; 32: 2940 â 2950.
dc.identifier.citedreferencePignon JP, le Maitre A, Maillard E, Bourhis J; MACHâ NC Collaborative Group. Metaâ analysis of chemotherapy in head and neck cancer (MACHâ NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4 â 14.
dc.identifier.citedreferenceRego DF, Elias ST, Amato AA, Canto GD, Guerra EN. Antiâ tumor effects of metformin on head and neck carcinoma cell lines: a systematic review. Oncol Lett. 2017; 13: 554 â 566.
dc.identifier.citedreferenceChae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016; 7: 40767 â 40780.
dc.identifier.citedreferenceYen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck. 2015; 37: 1268 â 1273.
dc.identifier.citedreferenceSandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck. 2014; 36: 1039 â 1043.
dc.identifier.citedreferenceCurry J, Johnson J, Tassone P, et al. Metformin effects on head and neck squamous carcinoma microenvironment: window of opportunity trial. Laryngoscope. 2017; 127: 1808 â 1815.
dc.identifier.citedreferenceRivadeneira DB, Delgoffe GM. Antitumor Tâ cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. Clin Cancer Res. 2018; 24: 2473 â 2481.
dc.identifier.citedreferenceScharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PDâ 1 blockade is potentiated by metforminâ induced reduction of tumor hypoxia. Cancer Immunol Res. 2017; 5: 9 â 16.
dc.identifier.citedreferenceNajjar YG, Menk AV, Sander C, et al. Tumor cell oxidative metabolism as a barrier to PDâ 1 blockade immunotherapy in melanoma. JCI Insight. 2019; 4 ( 5 ).
dc.identifier.citedreferenceStorozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of nonâ small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013; 108: 2021 â 2032.
dc.identifier.citedreferenceJi Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013; 31: 1785 â 1791.
dc.identifier.citedreferenceYang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B 12 levels, anemia, and neuropathy in patients with diabetes: a metaâ analysis. J Diabetes. 2019; 11: 729 â 743.
dc.identifier.citedreferenceGraham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50: 81 â 98.
dc.identifier.citedreferenceZazuli Z, Vijverberg S, Slob E, et al. Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol. 2018; 9: 1111.
dc.identifier.citedreferenceSafirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984; 25: 753 â 758.
dc.identifier.citedreferenceDobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cisâ platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 1980; 213: 551 â 556.
dc.identifier.citedreferenceRego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol. 2015; 51: 416 â 422.
dc.identifier.citedreferenceSkinner HD, Crane CH, Garrett CR, et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013; 2: 99 â 107.
dc.identifier.citedreferenceTrucco M, Barredo JC, Goldberg J, et al. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: metformin with induction chemotherapy of vincristine, dexamethasone, PEGâ asparaginase, and doxorubicin. Pediatr Blood Cancer. 2018; 65: e27224. doi: 10.1002/pbc.27224
dc.identifier.citedreferenceMorgillo F, Fasano M, Della Corte CM, et al. Results of the safety runâ in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, openâ label phase Iâ II study of metformin with erlotinib in secondâ line therapy of patients with stage IV nonâ smallâ cell lung cancer. ESMO Open. 2017; 2: e000132.
dc.identifier.citedreferenceClinicalTrials.gov. Chemotherapy and radiation therapy with or without metformin hydrochloride in treating patients with stage III nonâ small cell lung cancer. Accessed December 19, 2018. https://clinicaltrials.gov/ct2/show/NCT02186847
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32539.pdf
Size:
646.5KB
Format:
PDF
View/Open
Name:
cncr32539_am.pdf
Size:
364.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.